|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 8301 PROFESSIONAL PLACE WEST |
Address2 | Suite 230 |
| City | LANDOVER |
State | MD |
Zip Code | 20785-2353 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 13723-12
|
||||||||
|
6. House ID# 333440000
|
||||||||
| TYPE OF REPORT | 8. Year | 2020 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Abbey Roudebush |
Date | 4/20/2020 4:12:38 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
-Labor, Health and Human Services, Education and Related Agencies Appropriations Act, 2021, support funding for epilepsy programs and research including $11.5 million for the CDCs Epilepsy program, $44.7 billion for the NIH and $5 million for the National Neurological Conditions Surveillance System.
-Agriculture, Rural Development, Food and Drug Administration and Related Agencies Appropriations Act, 2021, support robust funding for the Food & Drug Administration.
-Defense Appropriations Act, 2021, support robust funding for the Congressionally Directed Medical Research Programs.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Laura |
Weidner |
|
|
|
Abbey |
Roudebush |
|
|
|
Rachel |
Patterson |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
-H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, support funding for agencies like the NIH, FDA and CDC to research, better treat and raise awareness and education about COVID-19, as well as support providing authority to relax restrictions in Medicare for telehealth services and reimbursement.
-H.R. 6201, Families First Coronavirus Response Act, support various provisions relevant to people with epilepsy including increased federal support for state Medicaid programs; funding for agencies to research, better treat and raise awareness and education about COVID-19; expansion of paid sick leave and paid family and medical leave; and free COVD-19 testing regardless of insurance type.
-H., CR. 748, CARES Act, support various provisions relevant to people with epilepsy and nonprofit support including access of up to a 90-day supply of medications through the pandemic; funding for agencies to research, better treat and raise awareness and education about COVID-19; prohibiting waivers of the Individuals with Disabilities Education Act (IDEA) and providing funding to ensure that special education needs are met through the pandemic; eligibility of Social Security beneficiaries for Economic Impact Payments and payments for Social Security beneficiaries without filing tax returns; grants to providers of Home and Community-Based Services; and allowing 501(c)(3) organizations and organizations that provide Medicaid services to apply for small business loans.
-H.R. 2279/S. 2546, Safe Step Act, support passage
-H.R. 3, Elijah Cummings Lower Drug Costs Now Act, support specific provisions such as an out-of-pocket cap in Medicare Part D and addition of language to ban the use of QALYs
-H.R. 3630, No Surprises Act; S. 1895, Lower Health Care Costs Act; S. 1531, the Stopping the Outrageous Practice of Surprise Medical Bills Act of 2019; H.R. 5800, Ban Surprise Billing Act; H.R. 5826 Consumer Protections Against Surprise Medical Bills Act, support passage of legislation to protect patients from surprise medical billing that holds patients harmless
-S. 2543, the Prescription Drug Pricing Reduction Act of 2019, support specific provisions such as an out-of-pocket cap in Medicare and improvements to the Medicaid Drug Rebate Program, as well as permanent authorization of the Money Follows the Person program. (Nicole and I did a bunch of these visits together since the two issues got linked).
-S. 1895, Lower Health Care Costs Act, support provisions to increase transparency and address anticompetitive practices in the prescription drug market
-H.R. 712, VA Medicinal Cannabis Research Act, support addition of epilepsy
-H.R. 2093/S. 1028, STATES Act, support passage
-H.R. 127, Compassionate Access, Research Expansion and Respect States (CARERS) Act, support passage
-H.R. 4322/S. 2400, Expanding Cannabis Research and Information Act, support passage
-FDA-2019-N-1428, Scientific Data and Information about Products Containing Cannabis or Cannabis-Derived Compounds, support preservation of meaningful access to cannabis and cannabis-derived products, including CBD tinctures with therapeutic levels of the cannabinoid, and creation of a regulatory framework that ensures that there is consistency in available products, manufacturing, safety, testing, and labeling standards, and increases the availability of important information such as potential side effects and drug interactions so that consumers and practitioners may be better informed
-H.R. 2035/S. 995, Lifespan Respite Reauthorization Act, support passage.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Abbey |
Roudebush |
|
|
|
Laura |
Weidner |
|
|
|
Rachel |
Patterson |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CIV
16. Specific lobbying issues
-H.R. 1549, Air Carrier Access Amendments Act, support passage to make air travel more accessible for people with disabilities
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Rachel |
Patterson |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |